The phase III INDIGO study demonstrated the efficacy of an IDH inhibitor, vorasidenib, in patients with residual or recurrent grade 2 IDH-mutant gliomas after surgery alone [15]. The gene discussed is IDH1; the disease is central nervous system cancer.